UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

210

7590

11/24/2008

EXAMINER
BRADLEY, CHRISTINA

CHNISTINA

PAPER NUMBER

MERCK AND CO., INC P O BOX 2000 RAHWAY, NJ 07065-0907

ART UNIT

DATE MAILED: 11/24/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/591,820	09/07/2006	William K. Hagmann	21643YP	4661

TITLE OF INVENTION: VLA-4 ANTAGONISTS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	02/24/2009

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where

appropriate. All further indicated unless correcte maintenance fee notificate	correspondence including below or directed other tions	ng the Patent, advance on nerwise in Block 1, by (a	ders and notification of n a) specifying a new corres	naintenance fees will pondence address; a	ll be mailed to the current and/or (b) indicating a sepa	correspondence address as arate "FEE ADDRESS" for
		ock 1 for any change of address)	Fee(s) Transmittal. This rs. Each additional	certificate cannot be used f	or domestic mailings of the for any other accompanying int or formal drawing, must
MERCK AND P O BOX 2000 RAHWAY, NJ (CO., INC	/2008	I her State addr trans	Certi reby certify that this es Postal Service wit essed to the Mail mitted to the USPT	ficate of Mailing or Trans Fee(s) Transmittal is being th sufficient postage for fir Stop ISSUE FEE address O (571) 273-2885, on the d	mission g deposited with the United st class mail in an envelope above, or being facsimile ate indicated below.
						(Depositor's name)
						(Signature)
						(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	2	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/591,820 FITLE OF INVENTION	09/07/2006 : VLA-4 ANTAGONIS	TS	William K. Hagmann		21643YP	4661
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE	FEE TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	02/24/2009
EXAM	INER	ART UNIT	CLASS-SUBCLASS			
BRADLEY, 0	CHRISTINA	1654	514-019000			
 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. 2. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 			or agents OR, alternative (2) the name of a single registered attorney or a	up to 3 registered patent attorneys rrnatively, single firm (having as a member a y or agent) and the names of up to tt attorneys or agents. If no name is		
PLEASE NOTE: Unl recordation as set forti (A) NAME OF ASSIG	less an assignee is ident h in 37 CFR 3.11. Comp GNEE	ified below, no assignee oletion of this form is NO	(B) RESIDENCE: (CITY	ntent. If an assigned assignment. and STATE OR CC	OUNTRY)	ocument has been filed for
			• .			oup entity Government
4a. The following fee(s) are submitted: ☐ Issue Fee ☐ Publication Fee (No small entity discount permitted) ☐ Advance Order - # of Copies			A check is enclosed. Payment by credit care	d. Form PTO-2038 i	e the required fee(s), any de	
	tus (from status indicate s SMALL ENTITY state		☐ b. Applicant is no lone	vor claiming SMALI	L ENTITY status. See 37 C	EP 1 27(a)(2)
						ne assignee or other party in
Authorized Signature				Date		
Typed or printed name				Registration No	·	
an application. Confident submitting the completed his form and/or suggesti	tiality is governed by 35 d application form to the ions for reducing this but firginia 22313-1450. DC	U.S.C. 122 and 37 CFR USPTO. Time will vary rden, should be sent to the	1.14. This collection is est depending upon the indiv e Chief Information Office	imated to take 12 mi idual case. Any com r. U.S. Patent and T	inutes to complete, includir nments on the amount of ti rademark Office, U.S. Den	d by the USPTO to process) ig gathering, preparing, and me you require to complete artment of Commerce, P.O. for Patents, P.O. Box 1450,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/591,820 09/07/2006		William K. Hagmann	21643YP	4661	
210 75	590 11/24/2008		EXAM	INER	
MERCK AND CO., INC			BRADLEY, CHRISTINA		
P O BOX 2000			ART UNIT	PAPER NUMBER	
RAHWAY, NJ 070	065-0907		1654		
			DATE MAILED: 11/24/200	8	

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 215 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 215 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

	Application No.	Applicant(s)	
	10/591,820	HAGMANN ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Christina Marchetti Bradley	1654	
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this or other appropriate communicate tIGHTS. This application is subject and MPEP 1308.	application. If not included ion will be mailed in due course. THIS	
1. This communication is responsive to the response filed 08	<u>3/11/2008</u> .		
2. ⊠ The allowed claim(s) is/are <u>1-9</u> .			
 Acknowledgment is made of a claim for foreign priority u a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). 	e been received. e been received in Application No.		
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submin INFORMAL PATENT APPLICATION (PTO-152) which giv	MENT of this application. nitted. Note the attached EXAMINI	ER'S AMENDMENT or NOTICE OF	
<u> </u>	. , ,	aration is deficient.	
 CORRECTED DRAWINGS (as "replacement sheets") mu (a) ☐ including changes required by the Notice of Draftspers 		O 048) attached	
	-	O-940) attached	
(b) ☐ including changes required by the attached Examiner Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1	's Amendment / Comment or in the		
each sheet. Replacement sheet(s) should be labeled as such in			
 DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT 			
 Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO/SB/08),	 5. ☐ Notice of Informa 6. ☐ Interview Summa Paper No./Mail I 7. ☒ Examiner's Amer 8. ☒ Examiner's State 	ary (PTO-413), Date	
of Biological Material	9.		
/Christina Marchetti Bradley/ Examiner, Art Unit 1654	/Cecilia Tsang/ Supervisory Patent I	Examiner, Art Unit 1654	

Application/Control Number: 10/591,820 Page 2

Art Unit: 1654

EXAMINER'S AMENDMENT

1. Claims 1-9 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 10-12, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

- 2. Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 06/09/2008 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.
- 3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
- 4. In a telephone conversation with Mollie M. Yang on 11/12/2008, Applicant was advised that claims 1-9 are allowable and that claims 10-12 are rejoined but subject to rejection under 35 U.S.C. 101 and 112, first and second paragraphs. To advance prosecution, Applicant agreed to cancel claims 10-12.

Application/Control Number: 10/591,820

Page 3

Art Unit: 1654

5. Authorization for this examiner's amendment was given in a telephone interview with Mollie M. Yang on 11/12/2008.

- 6. The application has been amended as follows:
- 7. Insert a period at the end of claim 8.
- 8. Cancel claims 10-12.
- 9. The following is an examiner's statement of reasons for allowance. The claims of the instant application are drawn to substituted N-[N-(cyanophenyl)sulfonoyl-prolyl-phenylalanine derivatives of formula I.

10. The closest prior art of Doherty *et al.* (U.S. Patent No. 6,943,180) teaches N-arylsulfonyl-prolyl-phenylalanine derivatives of the following formula:

including the preferred subgenus

Application/Control Number: 10/591,820 Page 4

Art Unit: 1654

 $\begin{array}{c} I_{3} \\ R^{43} \\ R^{34} \\ R^{2} \\ R^{2}$

Although the compounds of Doherty *et al.* share a common core with the instant invention,

Doherty *et al.* do not teach or suggest the following: that cyano can be used to substitute the Ar¹ group; that the R^{4a} and R^{3a} are independently selected from H, -NR^dR^e, NR^dS(O)mR^e, -NR^dC(O)R^e, -NR^dC(O)OR^e and -NR^dC(O)NR^dR^e, with the proviso that R^{4a} and R^{3a} cannot both be H; that R^{4b} and R^{3b} are H; that R² is H or methyl; and that R¹ can be -(C₁₋₁₀)alkyl-O- C₁₋₁₀alkyl, (C₁₋₁₀alkyl)-OC(O)- C₁₋₁₀alkyl, -(C₁₋₁₀alkyl)-OC(O)-aryl, -(C₁₋₁₀alkyl)-CC(O)- C₁₋₁₀alkyl or -(C₁₋₁₀alkyl)N+(C₁₋₃alkyl)₃. Further, the reference does not provide any motivation to make such substitutions. Thus, the compounds of claims 1-9 are both novel and unobvious over Doherty *et al.*

The following additional documents are considered to be close prior art that do not teach or suggest the instant invention owing to nonobvious differences in the substitution of the phenyl (Ar¹) and prolyl groups: Thorsett *et al.* (U.S. Patent No. 6,583,139), Durette *et al.* (U.S. Patent No. 6,903,075), Durette *et al.* (U.S. Patent No. 6,291,511), Lin *et al.* (U.S. Patent No. 6,855,708), Doherty *et al.* (WO 02/074761), Lin *et al.* (U.S. Patent No. 6,559,174) and Doherty *et al.* (Bioorganic and Med. Chem. Let., **2003**, 13, 1891-1895).

Application/Control Number: 10/591,820

Art Unit: 1654

12. The following prior art documents teach compounds that are related to the instant invention but do not share a common core: Chen *et al.* (U.S. Patent No. 6,806,365, N-alkanoyl phenylalanine derivatives); Kaplan *et al.* (U.S. Patent No. 6,388,084, N-pyridinyl-N-acyl-L-phenylalanine derivatives); Hull *et al.* (U.S. Patent No. 6,288,267, thioamide derivatives of phenylalanine); Chen *et al.* (U.S. Patent No. 6,229,011, N-aroyl phenylalanine derivatives); Konradi *et al.* (U.S. Patent No. 7,008,949, N-[2-N',N'-diethylamino-5-aminosulfonylphenylpyrimidin-4-yl]-p-carbomyloxy-phenylalanine derivatives); and Tanaka *et al.* (U.S. Patent No. 6,855,706, phenylalanine derivatives).

Page 5

- 13. The compounds are enabled for preparation and use as VLA-4 antagonists. VLA-4 antagonists are known in the prior art to be useful as anti-inflammatory agents (Lin *et al.*, *Curr*. *Op. Chem. Biol.*, **1998**, *2*, 453-7, Yang *et al.*, *Med. Res. Rev.*, **2003**, *23*, 369-392) and specifically for the treatment of asthma (Lobb *et al.*, *Exp. Op. Investigational Drugs*, **1999**, *8*, 935-45) and multiple sclerosis and Crohn's disease (Tilley, *Exp. Op. Ther. Patents*, **2002**, *12*, 991-1008).
- 14. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 15. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christina Marchetti Bradley whose telephone number is (571)272-9044. The examiner can normally be reached on Monday-Thursday, 9:00 A.M. to 3:00 P.M.

Application/Control Number: 10/591,820 Page 6

Art Unit: 1654

16. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Cecilia Tsang can be reached on (571) 272-0562. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

17. Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Cecilia Tsang/ Supervisory Patent Examiner, Art Unit 1654 /Christina Marchetti Bradley/ Examiner, Art Unit 1654